Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?

Literature DB >> 26024652

Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?

Michael Fay¹, Richard Head, Jennifer Martin.

Abstract

Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous and changing genetic profiles is less clear. Whether it is efficient to continue diverting resources from combined biological and pharmacological approaches to trial new and existing genetic 'targeted therapies' for brain tumours is unknown but of developing concern in resource constrained environments.

Entities: Disease

Mesh：

Year: 2015 PMID： 26024652 DOI： 10.1007/s11060-015-1816-z

Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130

16 in total

1. Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy.

Authors: Kevin C Yao; Tadashi Komata; Yasuko Kondo; Takao Kanzawa; Seiji Kondo; Isabelle M Germano
Journal: J Neurosurg Date: 2003-02 Impact factor: 5.115

2. Inhibition of mutated BRAF in melanoma.

Authors: Taegyun Kim; Jihyun Kim; Min-Geol Lee
Journal: N Engl J Med Date: 2010-12-02 Impact factor: 91.245

3. Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?

Authors: Michael Weller
Journal: Neuro Oncol Date: 2013-07 Impact factor: 12.300

4. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.

Authors: Abdel Nasser Hosein; Yi Chieh Lim; Bryan Day; Brett Stringer; Stephen Rose; Richard Head; Leah Cosgrove; Peter Sminia; Michael Fay; Jennifer H Martin
Journal: J Neurooncol Date: 2015-02-04 Impact factor: 4.130

5. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.

Authors: Krista A Van Nifterik; Jaap Van den Berg; Ben J Slotman; M Vincent M Lafleur; Peter Sminia; Lukas J A Stalpers
Journal: J Neurooncol Date: 2011-10-26 Impact factor: 4.130

6. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors: M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal: EMBO J Date: 2001-12-17 Impact factor: 11.598

7. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

Authors: Dragana Milojkovic; Jane Apperley
Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531

Review 8. Current role of anti-angiogenic strategies for glioblastoma.

Authors: Alissa A Thomas; Antonio Omuro
Journal: Curr Treat Options Oncol Date: 2014-12

9. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Authors: Evanthia Galanis; Kurt A Jaeckle; Matthew J Maurer; Joel M Reid; Matthew M Ames; James S Hardwick; John F Reilly; Andrey Loboda; Michael Nebozhyn; Valeria R Fantin; Victoria M Richon; Bernd Scheithauer; Caterina Giannini; Patrick J Flynn; Dennis F Moore; James Zwiebel; Jan C Buckner
Journal: J Clin Oncol Date: 2009-03-23 Impact factor: 44.544